Free press releases distribution network?

Agency / Source: GenScript Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



GenScript Rush Gene Synthesis – Driving Molecular Biology Research Faster - GenScript USA, Inc., has recently launched Rush Gene Synthesis service in global marketon Dec. 22, 2011, and has achieved 100% success and on time delivery rates ever since its kick-off - GenScript.com
GenScript Rush Gene Synthesis – Driving Molecular Biology Research Faster

 

PRZOOM - /newswire/ - Piscataway, NJ, United States, 2012/05/03 - GenScript USA, Inc., has recently launched Rush Gene Synthesis service in global marketon Dec. 22, 2011, and has achieved 100% success and on time delivery rates ever since its kick-off - GenScript.com. 1548:HK

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

GenScript USA, Inc., an internationally recognized biology contract research organization (CRO) has recently launched Rush Gene Synthesis service in global marketon Dec. 22, 2011, and has achieved 100% success and on time delivery rates ever since its kick-off.

“Two decades ago, a 2 Kb gene took me nearly two years to obtain the construct using conventional PCR cloning technologies in my PhD research. I did believe this can be changed. Nowadays, GenScript rush gene synthesis service delivery synthetic genes in as little as 5 business days. The proprietary technology and a dedicated Rush Gene Service team are the key points to make GenScript Rush Gene Synthesis service a big success,” commented Frank Zhang, the CEO and co-founder of GenScript.

“Delivering synthetic genes in as little as 5 days, GenScript Rush Gene Synthesis service is not only fast but is accurate and worry-free to our customers,” says Frank,“all our synthesized genes are packed into cloning vectors, picked from single clones and fully sequence-verified before the delivery. Therefore, none of our customers is bothered with picking up the right gene from the tube. With this rush service, we aim to drive molecular biology research faster than ever.”

Besides the world-leading gene synthesis service, GenScript (genscript.com), as a contract research organization (CRO), also provides comprehensive services for biological research and early-phase drug discovery, such as bio-reagents, assay development & screening, lead optimization, antibody drug development and animal model services. The bio-reagents services include custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development. Headquartered in Piscataway, New Jersey, GenScript has three subsidiaries located in France, Japan, and China.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GenScript Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


GenScript Rush Gene Synthesis – Driving Molecular Biology Research Faster

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
GenScript |
Contact: Sally Wang - GenScript.com 
732-885-9188 info[.]genscript.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GenScript Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From GenScript Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today